^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Study of EGFR-TKI Combined with Bevacizumab in Patients with Stage IIIB/IVNon-Small-Cell Lung Cancer Harboring EGFR Mutation and PD-L1 Positive
Excerpt:
...PD-L1 positive subjects (PD-L1 >= 1%) were detected by immunohistochemistry. ...
Trial ID:
Source:
Title:
PD-1 antibody plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for patients with PD-L1 negative and EGFR/ALK wild-type advanced or metastatic non-squamous non-small cell lung cancer : an open-label, randomised, multicentre phase 3 trial
Excerpt:
...The research center must be able to provide documents on the expression level of pd-L1 in subjects' tumor tissues. ...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure
Published date:
04/25/2023
Excerpt:
The median PFS of patients with low expression of programmed death receptor-ligand 1 (PD-L1) [Tumor cell Proportion Score (TPS)<1%], moderate expression of PD-L1 (1%≤TPS≤49%), and high expression of PD-L1 (TPS≥50%) were 6.4 (95%CI: 4.8-8.0), 8.3 (95%CI: 7.3-9.3) and 10.6 months (95%CI: 7.2-14.1), respectively, and there were statistically significant differences (χ2=13.58, P<0.001)....NSCLC patients who failed EGFR-TKIs treatment can tolerate adverse reactions related to immunotherapy combined with chemotherapy and bevacizumab treatment. PFS is significantly prolonged in those aged≤65 years and those with moderate and high expression of PD-L1.
Secondary therapy:
Chemotherapy + Immunotherapy
DOI:
10.3760/cma.j.cn112137-20221101-02275.
Source:
Title:
Correlation of clinical outcomes with programmed death ligand-1 expression on liquid biopsy.
Published date:
05/26/2022
Excerpt:
Sixteen patients with plasma PD-L1 expression treated with front-line immunotherapy regimens including single-agent immune checkpoint inhibitors, and combinatorial chemo-immune or chemo-immune-bevacizumab regimens were assessed for overall survival (OS)....Median OS for the immunotherapy treated patients was thirteen months with a thirty percent three year landmark OS versus four months median OS and a ten percent three-year landmark OS for those treated with chemotherapy alone....Plasma cfRNA PD-L1 expression is predictive of a statistically significant survival benefit from immunotherapy treatment compared to chemotherapy in the first line treatment of advanced NSCLC.
DOI:
10.1200/JCO.2022.40.16_suppl.e21050
